Prot #U2-VEN-109: Phase I/II Study of Venetoclax in Combination with Ublituximab and Umbralisib (TGR-1202) in Patients with Relapsed or Refractory CLL/SLL

Project: Research project

Project Details

StatusActive
Effective start/end date4/12/194/12/24

Funding

  • TG Therapeutics, Inc. (Prot #U2-VEN-109)